EP1315459A1 - Method for transdermal nucleic acid sampling - Google Patents
Method for transdermal nucleic acid samplingInfo
- Publication number
- EP1315459A1 EP1315459A1 EP01962273A EP01962273A EP1315459A1 EP 1315459 A1 EP1315459 A1 EP 1315459A1 EP 01962273 A EP01962273 A EP 01962273A EP 01962273 A EP01962273 A EP 01962273A EP 1315459 A1 EP1315459 A1 EP 1315459A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- nucleic acid
- microprojections
- microprojection
- piercing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 59
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 59
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000005070 sampling Methods 0.000 title claims abstract description 21
- 210000003491 skin Anatomy 0.000 claims abstract description 73
- 210000004927 skin cell Anatomy 0.000 claims abstract description 21
- 210000002615 epidermis Anatomy 0.000 claims abstract description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 4
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 4
- 210000000434 stratum corneum Anatomy 0.000 claims description 21
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 7
- 239000012530 fluid Substances 0.000 abstract description 5
- 210000003470 mitochondria Anatomy 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 16
- 210000003722 extracellular fluid Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000001259 photo etching Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 229910000851 Alloy steel Inorganic materials 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- 229910001200 Ferrotitanium Inorganic materials 0.000 description 1
- 229910000927 Ge alloy Inorganic materials 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229910001260 Pt alloy Inorganic materials 0.000 description 1
- 229910001128 Sn alloy Inorganic materials 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 229910001297 Zn alloy Inorganic materials 0.000 description 1
- 229910001093 Zr alloy Inorganic materials 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B2010/008—Interstitial fluid
Definitions
- the present invention relates to nucleic acid (e.g., DNA or RNA) sampling. More particularly, this invention relates to transdermal nucleic acid sampling.
- the present invention uses skin-piercing microprojections to pierce skin cells and affect transdermal nucleic acid sampling.
- DNA testing is presently performed by blood sampling or tissue swabbing followed by polymerase chain reaction (PCR) amplification of the DNA and then analysis of the amplified DNA.
- Blood sampling using a syringe is invasive and painful. Tissue swabbing is inconvenient and uncomfortable for many patients.
- One common procedure for sampling DNA uses buccal mucosal tissue samples obtained by rotating cyto brushes vigorously along the inside of the cheek for about 30 seconds.
- nucleic acids for the purposes of genetic testing (e.g., paternity testing, matching blood/semen samples to individuals in police/criminal detective work), medical diagnostics (e.g., screening patients for the presence of a disease and/or for predisposition towards disease such as heart disease), and the like.
- genetic testing e.g., paternity testing, matching blood/semen samples to individuals in police/criminal detective work
- medical diagnostics e.g., screening patients for the presence of a disease and/or for predisposition towards disease such as heart disease
- the present invention provides a method for transdermal DNA sampling using a reproducible, high volume production, low-cost device.
- the invention comprises piercing through the outermost layer (i.e., the stratum corneum layer) of the skin and into the underlying epidermis layer, or into both the epidermis and dermis layers, with a plurality of microprojections.
- the method of the present invention can also be used to extract and sample nucleic acids released into the skin's interstitial fluid. As before, the outermost stratum corneum layer of the skin is pierced to form pathways through which the interstitial fluid, containing the nucleic acids, is withdrawn (i.e., sampled).
- the sampling device used with this embodiment of the present invention can apply a partial vacuum (also referred to herein as "negative pressure") to the microcut skin.
- the negative pressure causes interstitial fluid to efflux from the microcuts.
- the interstitial fluid is collected, the nucleic acids contained therein is amplified using standard polymerase chain reaction (PCR) techniques, and then the amplified nucleic acids are analyzed.
- the device for piercing the skin comprises a sheet having a plurality of openings therethrough, and a plurality of microprojections integral therewith and extending downward (i.e., in a direction toward the skin) therefrom.
- the optional negative pressure driven device applies a partial vacuum (i.e., suction) to the microcuts through the openings in the sheet.
- the use of a device for piercing the stratum corneum layer of skin for purposes of analyzing nucleic acid in an animal includes piercing through the stratum corneum layer of skin into at least an underlying epidermis layer with a skin-piercing microprojection and disrupting or dislodging skin cells containing nucleic acid. Nucleic acid from the disrupted or dislodged skin cells is collected and then analyzed.
- Figure 1 is an enlarged perspective view of the skin proximal side of the microprojection array device in accordance with one embodiment of the present invention
- Figure 2 is a partial top plan view of a microprojection array pattern in accordance with one embodiment of the present invention
- Figure 3 is a side sectional view of a microprojection DNA- sampling array held in place on the skin with an adhesive overlay
- Figure 4 is a side view of an optional negative pressure driven device with a microprojection DNA-sampling array shown in section.
- the present invention provides a bloodless and pain free method of obtaining a nucleic acid sample from the skin.
- nucleic acid(s) is used broadly to include DNA (i.e., deoxyribonucleic acid), DNA fragments, RNA (ribonucleic acid), RNA fragments, chromosomes, genes, and any other polynucleic acid sequence, or portion thereof, found in the nucleii and/or mitochondria of cells.
- the skin is pierced with at least one, preferably a plurality and more preferably a multiplicity of, tiny stratum corneum piercing microprojections.
- the present invention is not limited to microprojections of any size, shape or configuration, in order for the sampling
- the microprojections should pierce into the skin to a depth of about 25 ⁇ m to about 400 ⁇ m, and preferably to a depth of about 50 ⁇ m to about 300 ⁇ m. Piercing to this depth with a plurality of microprojections ensures little if any bleeding, no significant sensation (pain) and further ensures that the blades will penetrate through the outermost o stratum corneum layer of dead cells and into the epidermis layer, or into both the epidermis and dermis layers, which contain live skin cells.
- the piercing can be accomplished by impacting the microprojections against the skin surface using a device of the type disclosed in Figures 22 and 23 of Trautman et al., WO 01/41863 or using a conventional spring-loaded device of the type s used to drive a lancet into the skin for blood droplet sampling.
- the microprojections Upon piercing into the epidermal layer, the microprojections, which are typically large in relation to the typical 20 ⁇ m diameter of living epidermal skin cells, will puncture and/or break apart a number of skin cells in the epidermal layer, or in both the epidermal and dermal layers, causing those o cells to release their contents. This causes the skin cells' nucleii, and/or the nucleic acids originally contained in the skin cells' nucleii, to be released into the skin's extracellular fluid (also called interstitial fluid). This body fluid is coated onto the surfaces of the skin-piercing microprojections or absorbed into an absorbant coating on the microprojections.
- the skin piercing microprojections are typically made from either metal, plastic or silicon, any of which materials can be suitably coated with intracellular (from the ruptured skin cells) and extracellular body fluids, including the nucleic acids of the ruptured cells.
- the nucleic acid sample can simply be collected by immersing/incubating the microprojection in sterile water, optionally with surfactants, buffers and proteases.
- the target gene(s) in the DNA and/or RNA containing solution is amplified using known polymerase chain reaction techniques. These techniques are described for example in Saiki, et al, Primer-directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase, Science, 239, 487, 1988.
- Device 2 comprises a plurality of microprojections 4 (i.e., a microprojection array) extending downward from one surface of a sheet or plate 6 (see Figure 1 in which device 2 is in an inverted position to show the microprojections).
- the microprojections 4 penetrate through the stratum corneum layer and at least into the epidermis layer of the skin when the device is pressed against the skin to sample nucleic acid therethrough.
- the term "skin” as used herein refers to the skin of a living or dead animal, particularly a human, but specifically excludes mucosal membranes (e.g., the buccal mucosa).
- the device 2 preferably has a microprojection density of at least about 10 microprojections/cm 2 and more preferably at least about 50 microprojections/cm 2 .
- the number of openings per unit area of the plate 6 is typically at least about 10 openings/cm 2 and more typically at least about 100 openings/cm 2 .
- the microprojections 4 can be formed using a photo-etching process, which is described in Cormier, et al., WO 97/48440, the disclosures of which are incorporated herein by reference. This process allows the microprojections 4 to be reproducibly formed on a very small (i.e., tens of microns) scale.
- the plurality of microprojections 4 for puncturing the stratum corneum are present on one face surface 48 of the device 2 in any predetermined arrangement, for example, as a cluster of microprojections spaced in rows having any desired number, or in any spaced apart relation of one microprojection to each other.
- the device 2 of the embodiment shown in Figure 1 is produced by the pattern shown in Figure 2.
- Each microprojection has a width and thickness that facilitates penetration of the stratum corneum without bending.
- the required length of the microprojection is subject to variation of the skin being penetrated and corresponds to the natural thickness of the stratum corneum, for one of the principle features of the invention is that the microprojections are to penetrate the stratum corneum into the epidermis.
- microprojection length Another factor affecting microprojection length is the method of microprojection application since the microprojections frequently do not penetrate the skin to a depth equal to the microprojection length due to the elastic properties of living animal skin.
- the microprojections will be about 25 ⁇ m to about 500 ⁇ m in length, with the length most typically being between about 100 ⁇ m to about 450 ⁇ m.
- the pattern for any of the microprojection array devices used in the present invention may be produced with a photo-etching process.
- a thin sheet or plate 6 of metal such as stainless steel or titanium is etched photo-lithographically with patterns containing microblade-like structures.
- a thin laminate dry resist or wet resist is applied on a sheet about 7 ⁇ m to about 100 ⁇ m thick, preferably about 25 ⁇ m to about 50 ⁇ m thick.
- the resist is contact exposed using a mask having the desired pattern and is subsequently developed. These operations are conducted in much the same way that they are for the manufacture of a printed circuit board.
- the sheet is then etched using acidic solutions.
- the sheet is placed on a die having a plurality of openings corresponding to the openings 8 in the sheet.
- a punch having a plurality of protrusions corresponding to the openings in the sheet and die is initially located above the sheet and die.
- the microprotrusions 4 are in the same plane as the rest of the sheet 6.
- the protrusions on the punch are then pressed into the openings, thus bending the microprojections 4 downward to be at an angle (e.g., substantially perpendicular) to the plane of the sheet 6 as shown in Figure 1.
- the microprojections 4 are at an angle of about 90° to the surface 48 of the sheet 6 after being punched, but they can be disposed at other angles forward or backward from the perpendicular position as long as penetration of the stratum corneum is achieved.
- Another embodiment of the present invention extracts the DNA- containing intracellular and extracellular fluids from the microcuts formed by the skin piercing microprojections, wherein the fluid is extracted with a device which applys a partial vacuum to the surface of the skin. Referring now to Figure 4, there is shown a negative pressure driven device 10 having a microprojection array device 2 on the skin proximal side of device 10.
- Device 10 and device 2 are used for the transdermal sampling of interstitial fluid containing nucleic acids released from the skin cells that are pierced or broken apart by the skin piercing microprojections.
- Device 10 is a known negative pressure (i.e., suction) applying device such as that disclosed in Ishibashi, U.S. Patent 5,320,607, the disclosures of which are incorporated herein by reference.
- Device 10 is mounted on the skin distal surface of device 2. The skin proximal side of device 2 is in contact with the surface of skin 20, with the microprojections 4 extending at least through the stratum corneum layer of skin 20.
- the negative pressure applied by device 10 causes suction to be applied through the openings 8 in sheet 6.
- the nucleic acid-containing interstitial fluid is extracted out of the microcuts cut in the skin 20 and drawn into device 10.
- an uncoated microprojection array made of a sterilized metal such as stainless steel or titanium
- nucleic acid transfer/receiving layer coating the skin proximal side of plate 6.
- transfer/receiving layers are disclosed in Theeuwes, et al. WO 98/28037, the disclosures of which are incorporated herein by reference.
- the major barrier properties of the skin reside first with the walls of individual skin cells.
- the microprojections in device 2 must be sized, shaped and configured to pierce through the stratum corneum layer and disrupt the cell walls of living skin cells in the layer of skin just below the stratum corneum layer, without piercing into the capillary beds within the skin so as to avoid significant bleeding.
- the microprojections must create openings (i.e., microcuts) in the stratum corneum particularly for those embodiments which rely upon collecting the nucleic acid released from the skin cells into the interstitial fluid.
- openings i.e., microcuts
- the nucleic acid-containing intracellular and extracellular fluids coat the skin-piercing microprojections substantially instanteously as the microprojections pierce the skin, there is no need to keep the microprojection array anchored or otherwise attached to the skin for any appreciable length of time.
- the microprojection array should preferably be previously sterilized to avoid any possible cross-contamination, e.g., by picking up tissue or other nucleic acid- containing material from a source other than the test subject.
- the microprojection array and any device used to apply the microprojection array to the skin is manufactured as a single-use disposable device which is sterilized and placed in a sealed package prior to use.
- the sheet and microprojections can be made from materials that have sufficient strength and manufacturability to produce microprojections, such as, glasses, ceramics, rigid polymers, metals and metal alloys.
- metals and metal alloys include but are not limited to titanium, stainless steel, iron, steel, tin, zinc, copper, platinum, aluminum, germanium, nickel, zirconium, and titanium alloys consisting of nickel, molybdenum and chromium, metals plated with nickel, gold, rhodium, iridium, titanium, platinum, and the like.
- glasses include silicon and a devitrified glass such as "Photoceram” available from Corning in Corning, NY.
- rigid polymers include but are not limited to polystyrene, polymethylmethacrylate, polypropylene, polyethylene, "Bakelite", cellulose acetate, ethylcellulose, styrene/acrylonitrile copolymers, stryrenetbutadiene copolymers, acrylonitrile/butadiene/styrene (ABS) copolymers, polyvinyl chloride and acrylic acid polymers including polyacrylates and polymethacrylates.
- ABS acrylonitrile/butadiene/styrene
- the sheet and microprojections are made from titanium or stainless steel.
- the number of microblades and openings of any of the embodiments of the device 2 is variable with respect to the desired DNA sample size and whether or not a negative pressure driven sampling device is used, and other factors as will be evident to one of ordinary skill in the art.
- the following examples illustrate the uses and advantages of the present invention.
- EXAMPLE 1 Studies are performed in two siblings and four unrelated individuals. In each subject, the treatment site (ventral forearm) is cleaned with a 70% sterile isopropyl alcohol pad. The skin site is then dried with a sterile gauze pad. The skin is pierced by impacting a microprojection device against the skin surface using a spring-loaded applicator.
- the microprojection device includes a 1 cm 2 disk-shaped microprojection array having microprojections with a length of 200 ⁇ m and a density of 320 microprojections/cm 2 , adhered to a low density polyethylene backing with polyisobutylene adhesive.
- the system is immediately removed with sterile forceps and is transferred into a sterile vial and is stored frozen (-20°C) until analysis.
- additional DNA samples are obtained by swabbing the inside of the cheek for 30 seconds with a cytobrush which is immediately transferred into a sterile vial and stored frozen (-20°C) until analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
A minimally invasive transdermal nucleic acid sampling method comprises piercing through the outermost layer of the skin (20) and into the underlying epidermis with a plurality of microprojections (4). Living skin cells in the underlying epidermis are disrupted, causing them to release their contents including their nucleic acids (i.e., DNA, RNA, fragments thereof or other polynucleic acid material found in teh cleic and/or mitochondria of cells). The nucleic acid is collected on the surfaces of the microprojections and/or in a separate nucleic acid collection reservoir. The collected nucleic acid is then analyzed using standard polymerase chain reaction (PCR) techniques. Optionally a suction device (10) applies a partial vacuum through openings (8) in the microprojetion member (6) to the microcuts in the skin (20) for enhance defflux of intraelular and extracellular (i.e., body) fluids containing the nucleic acid.
Description
METHOD FOR TRANSDERMAL NUCLEIC ACID SAMPLING
Field of the Invention [0001] The present invention relates to nucleic acid (e.g., DNA or RNA) sampling. More particularly, this invention relates to transdermal nucleic acid sampling. The present invention uses skin-piercing microprojections to pierce skin cells and affect transdermal nucleic acid sampling.
Background of the Invention [0002] DNA testing is presently performed by blood sampling or tissue swabbing followed by polymerase chain reaction (PCR) amplification of the DNA and then analysis of the amplified DNA. Blood sampling using a syringe is invasive and painful. Tissue swabbing is inconvenient and uncomfortable for many patients. One common procedure for sampling DNA uses buccal mucosal tissue samples obtained by rotating cyto brushes vigorously along the inside of the cheek for about 30 seconds.
[0003] There have been many attempts to enhance transdermal flux by mechanically puncturing the skin prior to transdermal drug delivery. See for example U.S. Patent Nos. 5,279,544 issued to Gross et al., 5,250,023 issued to Lee et al., and 3,964,482 issued to Gerstel et al. These devices utilize solid and hollow microprojections to pierce the outer layer of the skin. [0004] There have also been attempts to sample body analytes (e.g., glucose) contained in interstitial fluid using devices having similar skin- piercing microprojections. The analyte content in the interstitial fluid is then correlated with that in the blood. See for example, Cormier et al.,
WO 97/48441 ; Joseph, U.S. Patent 5, 161 ,532; Erickson et al., U.S. Patent 5,582,184; Brinda, U.S. Patent 5,682,233; Erickson et al., U.S. Patent 5,746,217 and Erickson et al., U.S. Patent 5,820,570. Daddona et al., U.S. Patent 6,091 ,975 provides a diagnostic device having stratum corneum- piercing microprojections. Electrochemical sensors are placed directly on the microprojections for sensing/measuring body analyte concentrations such as blood glucose concentration. One of the advantages of sampling interstitial fluid is that the wound created in the skin is not as deep as the wound needed
for blood sampling. Thus, interstitial fluid sampling using such stratum corneum piercing microprojections is generally considered less invasive than blood sampling.
[0005] However, there is still a need for less invasive sampling of nucleic acids for the purposes of genetic testing (e.g., paternity testing, matching blood/semen samples to individuals in police/criminal detective work), medical diagnostics (e.g., screening patients for the presence of a disease and/or for predisposition towards disease such as heart disease), and the like.
Description of the Invention
[0006] The present invention provides a method for transdermal DNA sampling using a reproducible, high volume production, low-cost device. The invention comprises piercing through the outermost layer (i.e., the stratum corneum layer) of the skin and into the underlying epidermis layer, or into both the epidermis and dermis layers, with a plurality of microprojections.
Individual skin cells within the epidermis/dermis layers are pierced, causing the cellular contents, including the cells' nucleus and its nucleic acids, to be released. The nucleic acids are coated onto the surfaces of the microprojections and/or absorbed into an absorbant coating on the microprojections. The microprojections typically have a length of less than about 0.4 mm and a width and thickness which is even smaller. [0007] The method of the present invention can also be used to extract and sample nucleic acids released into the skin's interstitial fluid. As before, the outermost stratum corneum layer of the skin is pierced to form pathways through which the interstitial fluid, containing the nucleic acids, is withdrawn (i.e., sampled). Optionally, the sampling device used with this embodiment of the present invention can apply a partial vacuum (also referred to herein as "negative pressure") to the microcut skin. The negative pressure causes interstitial fluid to efflux from the microcuts. The interstitial fluid is collected, the nucleic acids contained therein is amplified using standard polymerase chain reaction (PCR) techniques, and then the amplified nucleic acids are analyzed.
[0008] In one aspect of the invention, the device for piercing the skin comprises a sheet having a plurality of openings therethrough, and a plurality of microprojections integral therewith and extending downward (i.e., in a direction toward the skin) therefrom. The optional negative pressure driven device applies a partial vacuum (i.e., suction) to the microcuts through the openings in the sheet.
[0009] In another aspect of the invention, the use of a device for piercing the stratum corneum layer of skin for purposes of analyzing nucleic acid in an animal is provided. The use includes piercing through the stratum corneum layer of skin into at least an underlying epidermis layer with a skin-piercing microprojection and disrupting or dislodging skin cells containing nucleic acid. Nucleic acid from the disrupted or dislodged skin cells is collected and then analyzed.
Brief Description of the Drawings
[00010] Figure 1 is an enlarged perspective view of the skin proximal side of the microprojection array device in accordance with one embodiment of the present invention; [00011] Figure 2 is a partial top plan view of a microprojection array pattern in accordance with one embodiment of the present invention; [00012] Figure 3 is a side sectional view of a microprojection DNA- sampling array held in place on the skin with an adhesive overlay; and [00013] Figure 4 is a side view of an optional negative pressure driven device with a microprojection DNA-sampling array shown in section.
Modes for Carrying Out the Invention [00014] The present invention provides a bloodless and pain free method of obtaining a nucleic acid sample from the skin. As used herein, the term "nucleic acid(s)" is used broadly to include DNA (i.e., deoxyribonucleic acid), DNA fragments, RNA (ribonucleic acid), RNA fragments, chromosomes, genes, and any other polynucleic acid sequence, or portion thereof, found in the nucleii and/or mitochondria of cells.
[00015] The skin is pierced with at least one, preferably a plurality and more preferably a multiplicity of, tiny stratum corneum piercing microprojections. Although the present invention is not limited to microprojections of any size, shape or configuration, in order for the sampling
5 to be painless and bloodless, the microprojections should pierce into the skin to a depth of about 25 μm to about 400 μm, and preferably to a depth of about 50 μm to about 300 μm. Piercing to this depth with a plurality of microprojections ensures little if any bleeding, no significant sensation (pain) and further ensures that the blades will penetrate through the outermost o stratum corneum layer of dead cells and into the epidermis layer, or into both the epidermis and dermis layers, which contain live skin cells. The piercing can be accomplished by impacting the microprojections against the skin surface using a device of the type disclosed in Figures 22 and 23 of Trautman et al., WO 01/41863 or using a conventional spring-loaded device of the type s used to drive a lancet into the skin for blood droplet sampling.
[00016] Upon piercing into the epidermal layer, the microprojections, which are typically large in relation to the typical 20 μm diameter of living epidermal skin cells, will puncture and/or break apart a number of skin cells in the epidermal layer, or in both the epidermal and dermal layers, causing those o cells to release their contents. This causes the skin cells' nucleii, and/or the nucleic acids originally contained in the skin cells' nucleii, to be released into the skin's extracellular fluid (also called interstitial fluid). This body fluid is coated onto the surfaces of the skin-piercing microprojections or absorbed into an absorbant coating on the microprojections. As a result, the cells' 5 nucleic acids become coated or absorbed on the skin piercing microprojections. The skin piercing microprojections are typically made from either metal, plastic or silicon, any of which materials can be suitably coated with intracellular (from the ruptured skin cells) and extracellular body fluids, including the nucleic acids of the ruptured cells. Once the nucleic acid- o containing fluids are coated onto the surfaces of the microprojections, the microprojections are removed from the skin, and the nucleic acid is collected for PCR amplification and later analysis. With typical metal, plastic or silicon based microprojections, the nucleic acid sample can simply be collected by
immersing/incubating the microprojection in sterile water, optionally with surfactants, buffers and proteases. The target gene(s) in the DNA and/or RNA containing solution is amplified using known polymerase chain reaction techniques. These techniques are described for example in Saiki, et al, Primer-directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase, Science, 239, 487, 1988.
[00017] After amplification of the target gene(s), analysis is performed using standard DNA analysis techniques, such as those described in Saiki, et al, Analysis of Enzymatically Amplified Beta-globin and HLA-DQA1 with Allele Specific Oligonucleotide Probes, Nature, 324, 163, 1986.
[00018] Turning now to the drawings in detail, one example of a skin piercing microprojection array device 2 for sampling nucleic acid according to the present invention is generally shown in Figure 1. Device 2 comprises a plurality of microprojections 4 (i.e., a microprojection array) extending downward from one surface of a sheet or plate 6 (see Figure 1 in which device 2 is in an inverted position to show the microprojections). The microprojections 4 penetrate through the stratum corneum layer and at least into the epidermis layer of the skin when the device is pressed against the skin to sample nucleic acid therethrough. The term "skin" as used herein refers to the skin of a living or dead animal, particularly a human, but specifically excludes mucosal membranes (e.g., the buccal mucosa). The device 2 preferably has a microprojection density of at least about 10 microprojections/cm2 and more preferably at least about 50 microprojections/cm2. In similar fashion, the number of openings per unit area of the plate 6 is typically at least about 10 openings/cm2 and more typically at least about 100 openings/cm2.
[00019] The microprojections 4 can be formed using a photo-etching process, which is described in Cormier, et al., WO 97/48440, the disclosures of which are incorporated herein by reference. This process allows the microprojections 4 to be reproducibly formed on a very small (i.e., tens of microns) scale.
[00020] The plurality of microprojections 4 for puncturing the stratum corneum are present on one face surface 48 of the device 2 in any
predetermined arrangement, for example, as a cluster of microprojections spaced in rows having any desired number, or in any spaced apart relation of one microprojection to each other. The device 2 of the embodiment shown in Figure 1 is produced by the pattern shown in Figure 2. Each microprojection has a width and thickness that facilitates penetration of the stratum corneum without bending. The required length of the microprojection is subject to variation of the skin being penetrated and corresponds to the natural thickness of the stratum corneum, for one of the principle features of the invention is that the microprojections are to penetrate the stratum corneum into the epidermis. Another factor affecting microprojection length is the method of microprojection application since the microprojections frequently do not penetrate the skin to a depth equal to the microprojection length due to the elastic properties of living animal skin. Usually, the microprojections will be about 25 μm to about 500 μm in length, with the length most typically being between about 100 μm to about 450 μm.
[00021] The pattern for any of the microprojection array devices used in the present invention may be produced with a photo-etching process. A thin sheet or plate 6 of metal such as stainless steel or titanium is etched photo-lithographically with patterns containing microblade-like structures. In general, a thin laminate dry resist or wet resist is applied on a sheet about 7 μm to about 100 μm thick, preferably about 25 μm to about 50 μm thick. The resist is contact exposed using a mask having the desired pattern and is subsequently developed. These operations are conducted in much the same way that they are for the manufacture of a printed circuit board. The sheet is then etched using acidic solutions. After the pattern has been etched through the sheet, the sheet is placed on a die having a plurality of openings corresponding to the openings 8 in the sheet. A punch having a plurality of protrusions corresponding to the openings in the sheet and die is initially located above the sheet and die. At the initial stage, the microprotrusions 4 are in the same plane as the rest of the sheet 6. The protrusions on the punch are then pressed into the openings, thus bending the microprojections 4 downward to be at an angle (e.g., substantially perpendicular) to the plane of the sheet 6 as shown in Figure 1.
[00022] Generally, the microprojections 4 are at an angle of about 90° to the surface 48 of the sheet 6 after being punched, but they can be disposed at other angles forward or backward from the perpendicular position as long as penetration of the stratum corneum is achieved. [00023] Another embodiment of the present invention extracts the DNA- containing intracellular and extracellular fluids from the microcuts formed by the skin piercing microprojections, wherein the fluid is extracted with a device which applys a partial vacuum to the surface of the skin. Referring now to Figure 4, there is shown a negative pressure driven device 10 having a microprojection array device 2 on the skin proximal side of device 10. Device 10 and device 2, in combination, are used for the transdermal sampling of interstitial fluid containing nucleic acids released from the skin cells that are pierced or broken apart by the skin piercing microprojections. Device 10 is a known negative pressure (i.e., suction) applying device such as that disclosed in Ishibashi, U.S. Patent 5,320,607, the disclosures of which are incorporated herein by reference. Device 10 is mounted on the skin distal surface of device 2. The skin proximal side of device 2 is in contact with the surface of skin 20, with the microprojections 4 extending at least through the stratum corneum layer of skin 20. By appropriately sealing the device 10 against the skin distal side of device 2, the negative pressure applied by device 10 causes suction to be applied through the openings 8 in sheet 6. In this manner, the nucleic acid-containing interstitial fluid is extracted out of the microcuts cut in the skin 20 and drawn into device 10. [00024] Although it is preferred to use an uncoated microprojection array made of a sterilized metal such as stainless steel or titanium, it is possible to coat the microprojections 4 and/or the skin proximal side of plate 6 with a thin coating of a fluid absorbing material, which can absorb and hold the nucleic acid-containing fluids upon piercing the stratum corneum. It is also possible to use a nucleic acid transfer/receiving layer coating the skin proximal side of plate 6. Such transfer/receiving layers are disclosed in Theeuwes, et al. WO 98/28037, the disclosures of which are incorporated herein by reference. [00025] The major barrier properties of the skin, such as resistance to nucleic acid efflux, reside first with the walls of individual skin cells. Thus, the
microprojections in device 2 must be sized, shaped and configured to pierce through the stratum corneum layer and disrupt the cell walls of living skin cells in the layer of skin just below the stratum corneum layer, without piercing into the capillary beds within the skin so as to avoid significant bleeding. Second, the microprojections must create openings (i.e., microcuts) in the stratum corneum particularly for those embodiments which rely upon collecting the nucleic acid released from the skin cells into the interstitial fluid. [00026] Because the nucleic acid-containing intracellular and extracellular fluids coat the skin-piercing microprojections substantially instanteously as the microprojections pierce the skin, there is no need to keep the microprojection array anchored or otherwise attached to the skin for any appreciable length of time. Thus, it is possible, though not necessary, to provide a conventional adhesive overlay to keep the microprojection array attached on to the skin for a short period of time. An example of such a system is disclosed in Figure 3 with a peripheral adhesive overlay 3 maintaining device 2 in piercing relation with skin 20. In any event, the microprojection array should preferably be previously sterilized to avoid any possible cross-contamination, e.g., by picking up tissue or other nucleic acid- containing material from a source other than the test subject. Most preferably, the microprojection array and any device used to apply the microprojection array to the skin is manufactured as a single-use disposable device which is sterilized and placed in a sealed package prior to use. [00027] The sheet and microprojections can be made from materials that have sufficient strength and manufacturability to produce microprojections, such as, glasses, ceramics, rigid polymers, metals and metal alloys.
Examples of metals and metal alloys include but are not limited to titanium, stainless steel, iron, steel, tin, zinc, copper, platinum, aluminum, germanium, nickel, zirconium, and titanium alloys consisting of nickel, molybdenum and chromium, metals plated with nickel, gold, rhodium, iridium, titanium, platinum, and the like. Examples of glasses include silicon and a devitrified glass such as "Photoceram" available from Corning in Corning, NY. Examples of rigid polymers include but are not limited to polystyrene, polymethylmethacrylate, polypropylene, polyethylene, "Bakelite", cellulose acetate, ethylcellulose,
styrene/acrylonitrile copolymers, stryrenetbutadiene copolymers, acrylonitrile/butadiene/styrene (ABS) copolymers, polyvinyl chloride and acrylic acid polymers including polyacrylates and polymethacrylates. Most preferably, the sheet and microprojections are made from titanium or stainless steel.
[00028] The number of microblades and openings of any of the embodiments of the device 2 is variable with respect to the desired DNA sample size and whether or not a negative pressure driven sampling device is used, and other factors as will be evident to one of ordinary skill in the art. The following examples illustrate the uses and advantages of the present invention.
EXAMPLE 1 [00029] Studies are performed in two siblings and four unrelated individuals. In each subject, the treatment site (ventral forearm) is cleaned with a 70% sterile isopropyl alcohol pad. The skin site is then dried with a sterile gauze pad. The skin is pierced by impacting a microprojection device against the skin surface using a spring-loaded applicator. The microprojection device includes a 1 cm2 disk-shaped microprojection array having microprojections with a length of 200 μm and a density of 320 microprojections/cm2, adhered to a low density polyethylene backing with polyisobutylene adhesive. Following application, the system is immediately removed with sterile forceps and is transferred into a sterile vial and is stored frozen (-20°C) until analysis. In the same subjects, additional DNA samples are obtained by swabbing the inside of the cheek for 30 seconds with a cytobrush which is immediately transferred into a sterile vial and stored frozen (-20°C) until analysis.
[00030] For analysis, the vials are sent to a contract laboratory specialized in DNA profiling. The DNA is extracted using standard procedures. Polymorphism for the gene DQA1 is assessed by PCR and reverse dot blot hybridization procedure. Results demonstrate that the two siblings are indeed related whereas the remaining individuals are unrelated to all. Identical results are obtained with the cytobrushes.
[00031] These results demonstrate the validity of the new nucleic acid sampling method. Applications include forensics, parenthood analysis, genetic testing for predisposition to genetic diseases and detection of infectious diseases. [00032] While the invention has been described in conjunction with the preferred specific embodiments thereof, it is to be understood that the foregoing description as well as the example are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
Claims
1. A method of transdermally sampling nucleic acid comprising: piercing through the stratum corneum layer of skin (20) into at least an underlying epidermis layer with a skin-piercing microprojection (4) and disrupting or dislodging skin cells containing nucleic acid; collecting nucleic acid from the disrupted or dislodged skin cells; and analyzing the nucleic acid.
2. The method of claim 1 , wherein the collecting step comprises coating the microprojection (4) with nucleic acid-containing body fluid and withdrawing the microprojection (4) from the skin (20).
3. The method of claim 2, including absorbing the body fluid into an absorbant material coating the microprojection (4).
4. The method of claim 1 , wherein the collecting step comprises collecting the nucleic acid released from the disrupted or dislodged skin cells into body fluid by applying negative pressure to the pierced skin (20).
5. The method of claim 1 , wherein the microprojection (4) pierces the skin (20) to a depth of less than about 500 μm.
6. The method of claim 1 , including piercing the skin (20) with a plurality of microprojections (4).
7. The method of claim 6, including piercing the skin (20) with a multiplicity of microprojections (4).
8. The method of claim 6, wherein the microprojections (4) pierce the skin (20) to a depth of at least about 25 μm.
9. The method of claim 6, wherein the microprojections (4) pierce the skin (20) at a density of at least about 10 microprojections/cm2.
10. The method of claim 6, wherein the nucleic acid is collected on surfaces of the microprojections (4).
11. The method of claim 1 , wherein the nucleic acid is collected in an absorbant matrix.
12. The method of claim 1 , wherein the nucleic acid is analyzed by polymerase chain reaction assay.
13. The method of claim 1 , wherein the skin (20) is the skin of a human.
14. The method of claim 1 , wherein the nucleic acid is selcted from the group consisting of DNA, DNA fragments, RNA, RNA fragments, genes, chromosomes, and polynucleic acid sequences.
15. Use of a device (6) for piercing the stratum corneum layer of skin (20) for analyzing nucleic acid of an animal by piercing through the stratum corneum layer of skin (20) into at least an underlying epidermis layer with a skin-piercing microprojection (4) and disrupting or dislodging skin cells containing nucleic acid; collecting nucleic acid from the disrupted or dislodged skin cells; and analyzing the nucleic acid.
16. The use of claim 15, wherein the collecting of nucleic acid comprises coating the microprojection (4) with nucleic acid-containing body fluid and withdrawing the microprojection (4) from the skin (20).
17. The use of claim 16, including absorbing the body fluid into an absorbant material coating the microprojection (4).
18. The use of claim 15, wherein the collecting of nucleic acid comprises collecting a body fluid containing the nucleic acid released from the disrupted or dislodged skin cells by applying negative pressure to the pierced skin (20).
19. The use of claim 15, wherein the microprojection (4) pierces the skin (20) to a depth of less than about 500 μm.
20. The use of claim 15, including piercing the skin (20) with a plurality of microprojections (4).
21. The use of claim 20, including piercing the skin (20) with a multiplicity of microprojections (4).
22. The use of claim 20, wherein the microprojections (4) pierce the skin (20) to a depth of at least about 25 μm.
23. The use of claim 20, wherein the microprojections (4) pierce the skin (20) at a density of at least about 10 microprojections/cm2.
24. The use of claim 20, wherein the nucleic acid is collected on surfaces of the microprojections (4).
25. The use of claim 15, wherein the nucleic acid is collected in an absorbant matrix.
26. The use of claim 15, wherein the nucleic acid is selcted from the group consisting of DNA, DNA fragments, RNA, RNA fragments, genes, chromosomes, and polynucleic acid sequences.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22767500P | 2000-08-24 | 2000-08-24 | |
| US227675P | 2000-08-24 | ||
| PCT/US2001/026102 WO2002015800A1 (en) | 2000-08-24 | 2001-08-20 | Method for transdermal nucleic acid sampling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1315459A1 true EP1315459A1 (en) | 2003-06-04 |
Family
ID=22854028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01962273A Withdrawn EP1315459A1 (en) | 2000-08-24 | 2001-08-20 | Method for transdermal nucleic acid sampling |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1315459A1 (en) |
| JP (1) | JP2004506914A (en) |
| KR (1) | KR20030068127A (en) |
| CN (1) | CN1471378A (en) |
| AU (2) | AU2001283469B2 (en) |
| CA (1) | CA2420343A1 (en) |
| MX (1) | MXPA03001694A (en) |
| WO (1) | WO2002015800A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004253571A1 (en) * | 2003-07-02 | 2005-01-13 | Alza Corporation | Microprojection array immunization patch and method |
| CN100367906C (en) * | 2004-12-08 | 2008-02-13 | 圣美迪诺医疗科技(湖州)有限公司 | Subcutaneous Implantable Biosensors |
| US8389215B2 (en) | 2007-07-26 | 2013-03-05 | University Of Utah Research Foundation | Non-invasive recovery of RNA and analysis of gene expression in skin |
| KR101032978B1 (en) * | 2009-04-29 | 2011-05-09 | 한국과학기술원 | Dumbbell set with motion feedback and motion recording using motion sensor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250067A (en) * | 1992-11-30 | 1993-10-05 | Ala Gelfer | Body treatment pad having a multiple number of sharpened skin-penetration protuberances |
| US6063082A (en) * | 1997-11-04 | 2000-05-16 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization basket delivery system and radiofrequency therapeutic device |
| US6551338B1 (en) * | 1999-09-01 | 2003-04-22 | Mcgill University | Method and device for myogenesis and angiogenesis of the heart |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
| EP0429842B1 (en) | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
| US5161532A (en) | 1990-04-19 | 1992-11-10 | Teknekron Sensor Development Corporation | Integral interstitial fluid sensor |
| US5279544A (en) | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
| JP2572823Y2 (en) | 1992-02-13 | 1998-05-25 | 株式会社アドバンス | Simple blood sampler |
| US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
| US5682233A (en) | 1995-09-08 | 1997-10-28 | Integ, Inc. | Interstitial fluid sampler |
| US7184826B2 (en) | 1996-06-18 | 2007-02-27 | Alza Corporation | Device and method for enhancing transdermal flux of agents being delivered or sampled |
| AU722574B2 (en) * | 1996-12-20 | 2000-08-10 | Alza Corporation | Device and method for enhancing transdermal agent flux |
| JP3097600B2 (en) * | 1997-05-30 | 2000-10-10 | 日本電気株式会社 | Stratum corneum puncture device |
| US6091975A (en) * | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| AU2189400A (en) * | 1998-12-18 | 2000-07-03 | Minimed, Inc. | Insertion sets with micro-piercing members for use with medical devices and methods of using the same |
| ATE310561T1 (en) | 1999-12-10 | 2005-12-15 | Alza Corp | APPARATUS AND METHOD FOR IMPROVING MICRONEEDLE SKIN PIERCING |
-
2001
- 2001-08-20 JP JP2002520715A patent/JP2004506914A/en active Pending
- 2001-08-20 AU AU2001283469A patent/AU2001283469B2/en not_active Ceased
- 2001-08-20 EP EP01962273A patent/EP1315459A1/en not_active Withdrawn
- 2001-08-20 KR KR10-2003-7002654A patent/KR20030068127A/en not_active Ceased
- 2001-08-20 WO PCT/US2001/026102 patent/WO2002015800A1/en not_active Ceased
- 2001-08-20 AU AU8346901A patent/AU8346901A/en active Pending
- 2001-08-20 CN CNA018178731A patent/CN1471378A/en active Pending
- 2001-08-20 MX MXPA03001694A patent/MXPA03001694A/en unknown
- 2001-08-20 CA CA002420343A patent/CA2420343A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250067A (en) * | 1992-11-30 | 1993-10-05 | Ala Gelfer | Body treatment pad having a multiple number of sharpened skin-penetration protuberances |
| US6063082A (en) * | 1997-11-04 | 2000-05-16 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization basket delivery system and radiofrequency therapeutic device |
| US6551338B1 (en) * | 1999-09-01 | 2003-04-22 | Mcgill University | Method and device for myogenesis and angiogenesis of the heart |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO0215800A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1471378A (en) | 2004-01-28 |
| KR20030068127A (en) | 2003-08-19 |
| CA2420343A1 (en) | 2002-02-28 |
| MXPA03001694A (en) | 2004-11-01 |
| AU8346901A (en) | 2002-03-04 |
| WO2002015800A1 (en) | 2002-02-28 |
| JP2004506914A (en) | 2004-03-04 |
| AU2001283469B2 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6749575B2 (en) | Method for transdermal nucleic acid sampling | |
| US6537264B1 (en) | Device and method for enhancing transdermal flux of agents being sampled | |
| US6091975A (en) | Minimally invasive detecting device | |
| KR100869655B1 (en) | Biological fluid constituent sampling and measurement devices | |
| TW592665B (en) | Method and device for sampling and analyzing interstitial fluid and whole blood samples | |
| CA2376128C (en) | Devices and methods for enhanced microneedle penetration of biological barriers | |
| CN1206004C (en) | Device for enhancing transdermal agent flux | |
| EP1006868B1 (en) | Minimally invasive detecting device | |
| US20030113827A1 (en) | Non-or minimally invasive monitoring methods | |
| JP2003516798A (en) | Device for increasing the transdermal flow rate of extracted drugs | |
| CZ20022023A3 (en) | Percutaneous biological fluid sampling and analyte measurement device | |
| WO2003052125A1 (en) | Non-or minimally invasive monitoring methods | |
| EP1713533A2 (en) | Method and/or apparatus for puncturing a surface for extraction, in situ analysis, and/or substance delivery using microneedles | |
| CZ20022020A3 (en) | Apparatus and method for percutaneous withdrawal of a biological liquid and analyte measuring | |
| JP3097600B2 (en) | Stratum corneum puncture device | |
| WO2008028087A2 (en) | Methods and apparatus incorporating a surface penetration device | |
| US20180256086A1 (en) | Microneedle Device for Interstitial Fluid Extraction | |
| EP1792565B1 (en) | Selectively exposable miniature probes with integrated sensor arrays for continuous in vivo diagnostics | |
| AU2001283469B2 (en) | Method for transdermal nucleic acid sampling | |
| AU2005200910B2 (en) | Devices and methods for enhanced microneedle penetration of biological barriers | |
| AU2001283469A1 (en) | Method for transdermal nucleic acid sampling | |
| US20240000442A1 (en) | Minimally invasive skin sample collection apparatus | |
| WO2018080923A1 (en) | Non-invasive passive interstitial fluid collector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20030321 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17Q | First examination report despatched |
Effective date: 20050602 |
|
| 17Q | First examination report despatched |
Effective date: 20050602 |
|
| 17Q | First examination report despatched |
Effective date: 20050602 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090303 |